Rystiggo is manufactured by UCB [1].
Who else makes treatments for generalized myasthenia gravis?
Other companies are also involved in the production of treatments for generalized myasthenia gravis. For example, Alexion, AstraZeneca's Rare Disease unit, manufactures Soliris and Ultomiris [2][3]. Additionally, Grifols produces Privigen [4].
What is Rystiggo used for?
Rystiggo (zilucoplan) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (anti-AChR) antibody positive [1]. gMG is a chronic autoimmune neuromuscular disease that can cause disabling symptoms [1].
How does Rystiggo work?
Rystiggo is a long-acting, targeted, reversible inhibitor of complement C5 [1]. By inhibiting C5, it prevents the formation of the membrane attack complex (MAC), which is implicated in the neuromuscular junction destruction seen in gMG [1].
When did Rystiggo get approved?
Rystiggo received approval from the U.S. Food and Drug Administration (FDA) in June 2023 [1].
What are the potential side effects of Rystiggo?
The most common side effects reported with Rystiggo include [1]:
* Diarrhea
* Headache
* Nausea
* Tingling or prickling sensation (paresthesia)
* Hair loss (alopecia)
* Skin reaction at the injection site
Rystiggo also carries a risk of meningococcal infections [1]. Patients must be vaccinated against Neisseria meningitidis before starting treatment [1].
Are there other treatments for gMG?
Yes, besides Rystiggo, other treatments for generalized myasthenia gravis include [2][3][4][5]:
* Soliris (eculizumab)
* Ultomiris (ravulizumab)
* Privigen (immune globulin intravenous)
* Various immunosuppressants and symptomatic treatments like pyridostigmine [5].
How is Rystiggo administered?
Rystiggo is administered as a subcutaneous injection once weekly [1].
What is the patent status for Rystiggo?
Information regarding the specific patents and their expiration dates for Rystiggo can be found on resources like DrugPatentWatch.com [6]. DrugPatentWatch.com tracks patent filings and grant dates for pharmaceutical products, which can indicate periods of market exclusivity.
How effective is Rystiggo in clinical trials?
In a clinical trial, Rystiggo demonstrated statistically significant improvements in the primary endpoint, the Myasthenia Gravis-Activities of Daily Living (MG-ADL) score, compared to placebo [1]. Patients treated with Rystiggo also showed improvements in other measures of gMG severity and quality of life [1].
What is the cost of Rystiggo?
Pricing details for Rystiggo are typically available through pharmaceutical pricing databases or upon direct inquiry with the manufacturer or specialty pharmacies. Information on drug costs can be complex and may vary based on insurance coverage and patient assistance programs.
Are there any contraindications for Rystiggo?
Rystiggo is contraindicated in patients with active Neisseria meningitidis infection [1].
What is generalized myasthenia gravis?
Generalized myasthenia gravis is a rare, chronic autoimmune neuromuscular disease that affects voluntary muscles [1][7]. In gMG, the immune system mistakenly attacks the connections between nerves and muscles, called acetylcholine receptors, disrupting nerve signal transmission and leading to muscle weakness [1][7]. This weakness can affect various parts of the body, including the eyes, face, throat, limbs, and breathing muscles [7].
---
Sources:
[1] https://www.drugpatentwatch.com/news/rystiggo-manufacturer
[2] https://www.drugpatentwatch.com/drug/soliris
[3] https://www.drugpatentwatch.com/drug/ultomiris
[4] https://www.drugpatentwatch.com/drug/privigen
[5] https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis
[6] https://www.drugpatentwatch.com/
[7] https://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/symptoms-causes/syc-20352054